Menu
Global
简体中文
繁体中文
English
Home
About Us
Company Introduction
Development History
Leadership Team
Honor and Qualification
Industry Chain
Corporate Culture
R & D
Therapeutic Area
Technology Platform
Innovative Pipeline
Partnering
Products
Oncology
Digestive
NASH
Investor
Stock Information
Announcements and Circulars
Financial Report
Corporate governance
Investor Calendar
Company Information
Prospectus
Investor Relations
News
Contact Us
Address
Contact Information
Adverse drug reaction report
Join XZenith
Our Culture
Careers
Benefit
Talent Development
Employee style
News center
Understanding Everything at a Glance | Xuanzhu Biology's Annual Performance for 2025
2026-03-31
Prev:2026 AACR Annual Conference Preview | Xuanzhu Biotech to Present groundbreaking research findings
Next:Enrollment completed! The Phase III clinical study of Anirazole Sodium Enteric-Coated Tablets for the treatment of reflux esophagitis has successfully enrolled its final subject.
Back List
Home
About Us
+
Company Introduction
Development History
Leadership Team
Honor and Qualification
Industry Chain
Corporate Culture
R & D
+
Therapeutic Area
Technology Platform
Innovative Pipeline
Partnering
Products
+
Oncology
Digestive
NASH
Investor
+
Stock Information
Announcements and Circulars
Financial Report
Corporate governance
Investor Calendar
Company Information
Prospectus
Investor Relations
News
+
Contact Us
+
Address
Contact Information
Adverse drug reaction report
Join XZenith
+
Our Culture
Careers
Benefit
Talent Development
Employee style